Alpha-synuclein stepwise aggregation reveals features of an early onset mutation in Parkinson’s disease

被引:0
|
作者
Guilherme A. P. de Oliveira
Jerson L. Silva
机构
[1] Federal University of Rio de Janeiro,Institute of Medical Biochemistry Leopoldo de Meis, National Institute of Science and Technology for Structural Biology and Bioimaging, National Center of Nuclear Magnetic Resonance Jiri Jonas
[2] University of Virginia,Department of Biochemistry and Molecular Genetics
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Amyloid formation is a process involving interconverting protein species and results in toxic oligomers and fibrils. Aggregated alpha-synuclein (αS) participates in neurodegenerative maladies, but a closer understanding of the early αS polymerization stages and polymorphism of heritable αS variants is sparse still. Here, we distinguished αS oligomer and protofibril interconversions in Thioflavin T polymerization reactions. The results support a hypothesis reconciling the nucleation-polymerization and nucleation-conversion-polymerization models to explain the dissimilar behaviors of wild-type and the A53T mutant. Cryo-electron microscopy with a direct detector shows the polymorphic nature of αS fibrils formed by heritable A30P, E46K, and A53T point mutations. By showing that A53T rapidly nucleates competent species, continuously elongates fibrils in the presence of increasing amounts of seeds, and overcomes wild-type surface requirements for growth, our findings place A53T with features that may explain the early onset of familial Parkinson’s disease cases bearing this mutation.
引用
收藏
相关论文
共 50 条
  • [31] ALPHA-SYNUCLEIN AGGREGATION AND SYNAPTIC PATHOLOGY IN PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES
    Stefanis, Leonidas
    NEUROBIOLOGY OF AGING, 2016, 39 : S4 - S4
  • [32] The Role of Alpha-Synuclein Oligomerization and Aggregation in Cellular and Animal Models of Parkinson's Disease
    Wan, Oi Wan
    Chung, Kenny K. K.
    PLOS ONE, 2012, 7 (06):
  • [33] Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson's disease
    Raichur, A.
    Vali, S.
    Gorin, F.
    NEUROSCIENCE, 2006, 142 (03) : 859 - 870
  • [34] Parkinson's disease, a dying back pathology associated with synaptic alpha-synuclein aggregation
    Spillantini, M. G.
    FEBS JOURNAL, 2011, 278 : 50 - 50
  • [35] Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson's disease
    Tsika, E.
    Davranche, A.
    Gabellieri, E.
    Nampally, S.
    Molette, J.
    Papin, S.
    Kroth, H.
    Pfeifer, A.
    Lowe, D.
    Muhs, A.
    MOVEMENT DISORDERS, 2016, 31 : S640 - S640
  • [36] Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity
    Wang, Peng
    Li, Xin
    Li, Xuran
    Yang, Weiwei
    Yu, Shun
    PARKINSONS DISEASE, 2016, 2016
  • [37] Parkinson's Disease, Cortical Dysfunction, and Alpha-Synuclein
    Caviness, John N.
    Lue, Lih-Fen
    Beach, Thomas G.
    Hentz, Joseph G.
    Adler, Charles H.
    Sue, Lucia
    Sadeghi, Ramin
    Driver-Dunckley, Erika
    Evidente, Virgilio G.
    Sabbagh, Marwan N.
    Shill, Holly A.
    Walker, Douglas G.
    MOVEMENT DISORDERS, 2011, 26 (08) : 1436 - 1442
  • [38] Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease
    Fields, Carroll Rutherford
    Bengoa-Vergniory, Nora
    Wade-Martins, Richard
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2019, 12
  • [39] Modeling Parkinson's Disease With the Alpha-Synuclein Protein
    Gomez-Benito, Monica
    Granado, Noelia
    Garcia-Sanz, Patricia
    Michel, Anne
    Dumoulin, Mireille
    Moratalla, Rosario
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [40] Alpha-synuclein and the prion hypothesis in Parkinson's disease
    Melki, R.
    REVUE NEUROLOGIQUE, 2018, 174 (09) : 644 - 652